Streetwise Articles



Biotech's Target Price Increased as Shares 'Deeply Undervalued'
Source: Streetwise Reports  (11/15/17)
Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer.
More >


John McCamant

Biotech Targets 'Blockbuster' Markets; Less-Addictive Opioid Painkiller Set for FDA Filing
Source: John McCamant for Streetwise Reports  (11/15/17)
Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer.
More >


Rick Mills

The Lowdown on Getting High in Canada
Source: Rick Mills for Streetwise Reports  (11/14/17)
Some 600 tonnes of marijuana a year are up for grabs as Canada moves to legalize weed, says Rick Mills, founder of Ahead of the Herd, who puts forth his case on why cannabis stocks should be in every investor's portfolio. More >


Analyst Says Biotech Share Price Could Potentially 'Double'
Source: Streetwise Reports  (11/13/17)
Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17. More >


Biotech with Solid Pipeline and 'Solid Partnership Outlook'
Source: Streetwise Reports  (11/13/17)
Analyst Kevin DeGeeter, with Ladenburg Thalmann, relayed the highlights from his recent meeting with this company's management team about near-term clinical news and pipeline plans.
More >


Biotech Reports Positive Topline Data; Biologics License Application in Progress
Source: Streetwise Reports  (11/6/17)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., reviewed the recent clinical trial results released by this developer of cell therapies targeting oncology and orphan indications.
More >


Target Price Raised on 'Undervalued' Antibiotics Developer
Source: Streetwise Reports  (11/6/17)
Analyst Ed Arce discussed the rationale behind H.C. Wainwright & Co.'s decision to revise its models on this clinical-stage biopharmaceutical company. More >


Could a FDA Warning Letter Provide a Silver Lining to This Home Care Medical Device Company?
Source: Maj Soueidan for Streetwise Reports  (11/6/17)
Maj Soueidan, cofounder of GeoInvesting, profiles his long history with a company providing medical devices for the home care market. More >


John McCamant

Drug Offers 'Best-in-Class' Potential
Source: John McCamant for Streetwise Reports  (11/1/17)
John McCamant, editor of the Medical Technology Stock Letter, initiated coverage on a company that he calls an emerging leader in women's health. More >


Big Biotech's Value Is Bolstered by Focus on Alzheimer's Disease
Source: Streetwise Reports  (11/1/17)
An analysis of this company's quarterly update highlights a pipeline studded with candidates targeting neurological indications. More >


Biopharmaceutical Firm Receives FDA Priority Review and PDUFA Date
Source: Streetwise Reports  (10/25/17)
Neil Maruoka, an analyst with Canaccord Genuity, provided an update on this biotech's progress through the regulatory approval process for one of its therapeutics. More >


Analyst Calls Biotech with Alzheimer's Therapy a 'High Risk, High Reward Opportunity'
Source: Streetwise Reports  (10/25/17)
Mackie Research reported on this company's recent announcement about one of its product candidates targeting Alzheimer's disease. More >


Coverage Initiated on Gene Therapy Company
Source: Streetwise Reports  (10/25/17)
Analyst David Nierengarten with Wedbush explained the rationale for adding this biotech to his coverage universe.
More >


Biotech Receives Device Approval in Five More Countries; Revenue Up 122% YOY
Source: Streetwise Reports  (10/25/17)
Maxim Group reported on this firm's Q3/17 earnings, as well as its progress in obtaining international regulatory clearances for its medical system.
More >


Biotech Announces 'Late-Breaking' Addition to Immunotherapy Conference
Source: Streetwise Reports  (10/18/17)
Michael King Jr., an analyst with JMP Securities, reported this biopharmaceutical firm was recently added to the roster of presenters scheduled for an upcoming annual meeting. More >


Biotech Releases Initial Zika Vaccine Trial Results; Advances Combo Trials
Source: Streetwise Reports  (10/18/17)
With multiple candidates in the pipeline advancing through clinical trials, Ram Selvaraju, an analyst with H.C. Wainwright & Co., provided insight into developments at a biotech addressing Zika virus, advanced bladder cancer and cervical dysplasia.
More >


Reliq Health Technologies Quickly Gaining Traction in Fast Growing Telemedicine Market
Source: Streetwise Reports  (10/11/17)
The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, and Reliq Health Technologies is adding thousands of patients to its rolls. More >


Cannabis Company Forms Partnership to Develop Pharmaceuticals
Source: Streetwise Reports  (10/6/17)
Analyst Russell Stanley with Echelon Wealth Partners explained the significance of the recent licensing agreement signed by this Canadian medical marijuana producer and distributor. More >


Telemedicine Platform Is Quickly Gaining Traction in Fast Growing Market
Source: Streetwise Reports  (10/5/17)
The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market. More >


Reliq Health Technologies Quickly Gaining Traction in Rapidly Growing Telemedicine Market
Source: Streetwise Reports  (10/5/17)
The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market. More >


Colin Lee Novick

Japan Is Fertile Ground for Biotech Deals
Source: Streetwise Reports  (10/4/17)
Japan and the United States are hotspots for companies that are looking to license-out exciting regenerative medicine technology, says Colin Lee Novick, managing director of CJ PARTNERS. In this interview with The Life Sciences Report, Novick discusses a regenerative medicine company pursuing partnerships in Japan for its cell therapies to treat chronic tendinosis, damaged or aged skin, and pattern baldness. More >


Small Biotech Enters Patent Deal with British Company Targeting Schizophrenia
Source: Streetwise Reports  (10/4/17)
A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.
More >


Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End
Source: Streetwise Reports  (10/4/17)
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi.
More >


Immunotherapy Firm's Technology Demonstrates 'Potential Use in Treating Cancers and Bacterial Infections'
Source: Streetwise Reports  (9/27/17)
H.C. Wainwright & Co. reported the results of animal studies conducted using therapeutics created by this cancer and chronic infectious disease vaccine developer. More >


Possible 'Best-in-Class' Alzheimer's Drug Candidate Offers 'Disruptive' Potential
Source: Streetwise Reports  (9/20/17)
André Uddin, an analyst with Mackie Research, explained the rationale for adding this neurodegenerative disease biotech company to his firm's coverage universe. More >


Showing Results: 1 to 25 of 812 Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe